MX2021001563A - Uso de tabletas de desintegracion oral de riluzol para tratar enfermedades. - Google Patents

Uso de tabletas de desintegracion oral de riluzol para tratar enfermedades.

Info

Publication number
MX2021001563A
MX2021001563A MX2021001563A MX2021001563A MX2021001563A MX 2021001563 A MX2021001563 A MX 2021001563A MX 2021001563 A MX2021001563 A MX 2021001563A MX 2021001563 A MX2021001563 A MX 2021001563A MX 2021001563 A MX2021001563 A MX 2021001563A
Authority
MX
Mexico
Prior art keywords
riluzole
oral
disintigrating
tablets
treating diseases
Prior art date
Application number
MX2021001563A
Other languages
English (en)
Spanish (es)
Inventor
Vladimir Coric
Original Assignee
Biohaven Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Therapeutics Ltd filed Critical Biohaven Therapeutics Ltd
Publication of MX2021001563A publication Critical patent/MX2021001563A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/428Thiazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2063Proteins, e.g. gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MX2021001563A 2018-08-16 2019-08-15 Uso de tabletas de desintegracion oral de riluzol para tratar enfermedades. MX2021001563A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862764864P 2018-08-16 2018-08-16
PCT/US2019/046709 WO2020037152A1 (en) 2018-08-16 2019-08-15 Use of riluzole oral disintigrating tablets for treating diseases

Publications (1)

Publication Number Publication Date
MX2021001563A true MX2021001563A (es) 2021-06-15

Family

ID=69525906

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021001563A MX2021001563A (es) 2018-08-16 2019-08-15 Uso de tabletas de desintegracion oral de riluzol para tratar enfermedades.
MX2024007642A MX2024007642A (es) 2018-08-16 2021-02-08 Uso de tabletas de desintegracion oral de riluzol para tratar enfermedades.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2024007642A MX2024007642A (es) 2018-08-16 2021-02-08 Uso de tabletas de desintegracion oral de riluzol para tratar enfermedades.

Country Status (15)

Country Link
US (1) US20210315865A1 (https=)
EP (1) EP3836922B1 (https=)
JP (2) JP2021534160A (https=)
KR (1) KR20210045423A (https=)
CN (1) CN112584831A (https=)
AU (1) AU2019322889A1 (https=)
BR (1) BR112021002692A2 (https=)
CA (1) CA3109769A1 (https=)
EA (1) EA202190544A1 (https=)
ES (1) ES2987802T3 (https=)
IL (1) IL280657A (https=)
MX (2) MX2021001563A (https=)
PH (1) PH12021550218A1 (https=)
SG (1) SG11202100880VA (https=)
WO (1) WO2020037152A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230027189A (ko) * 2020-06-24 2023-02-27 바이오하벤 테라퓨틱스 리미티드 강박 장애를 치료하기 위한 조성물 및 방법
EP4240308A4 (en) * 2020-10-05 2024-10-30 Icahn School of Medicine at Mount Sinai Riluzole for the treatment of alzheimer's disease
WO2022103638A1 (en) 2020-11-16 2022-05-19 Orcosa Inc. Cannabinoids in the treatment of autism spectrum disorder
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
CN114177153B (zh) * 2021-12-20 2023-04-07 平顶山市第二人民医院 一种利鲁唑口崩片及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
GB9908014D0 (en) 1999-04-08 1999-06-02 Scherer Corp R P Pharmaceutical compositions
MXPA05005528A (es) * 2002-11-26 2006-04-05 Alk Abello As Producto farmaceutico de alergeno.
US9241902B2 (en) * 2003-12-17 2016-01-26 R.P. Scherer Technologies, Llc Chewable soft capsules containing ungelatinized starch
US8778979B2 (en) * 2005-04-05 2014-07-15 Yale University Glutamate agents in the treatment of mental disorders
US20080260823A1 (en) * 2007-04-20 2008-10-23 Sciele Pharma, Inc. Orally disintegrating tablet comprising glycopyrrolate for treating sialorrhea
PT2467372T (pt) * 2009-08-10 2016-08-23 Teva Pharma Tratamento de distúrbios relacionados com bdnf usando laquinimod
US9041556B2 (en) 2011-10-20 2015-05-26 Apple Inc. Method for locating a vehicle
US9434704B2 (en) * 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
EA038518B1 (ru) * 2014-11-21 2021-09-09 Биохэйвен Фармасьютикал Холдинг Компани Лтд. Сублингвальный препарат рилузола
MX2017006454A (es) * 2014-11-21 2018-03-23 Biohaven Pharm Holding Co Ltd Administracion sublingual de riluzol.
WO2016085998A1 (en) * 2014-11-26 2016-06-02 Medicinova, Inc. Combination of ibudilast and riluzole and methods of using same
RS62915B1 (sr) * 2015-03-03 2022-03-31 Biohaven Therapeutics Ltd Prolekovi riluzola i njihova primena
JP2020506231A (ja) * 2017-01-31 2020-02-27 パオロ エル マンフレディ 神経系の障害並びにその症状及び徴候の処置又は予防のため並びに疾患及び細胞の老化並びにその症状及び徴候に対する細胞保護のための化合物

Also Published As

Publication number Publication date
EP3836922B1 (en) 2024-08-07
IL280657A (en) 2021-03-25
WO2020037152A1 (en) 2020-02-20
JP2024010017A (ja) 2024-01-23
ES2987802T3 (es) 2024-11-18
JP2021534160A (ja) 2021-12-09
CN112584831A (zh) 2021-03-30
AU2019322889A1 (en) 2021-03-04
SG11202100880VA (en) 2021-02-25
US20210315865A1 (en) 2021-10-14
PH12021550218A1 (en) 2021-12-06
EA202190544A1 (ru) 2021-06-18
BR112021002692A2 (pt) 2021-05-11
MX2024007642A (es) 2024-07-04
CA3109769A1 (en) 2020-02-20
EP3836922A1 (en) 2021-06-23
KR20210045423A (ko) 2021-04-26
EP3836922C0 (en) 2024-08-07
EP3836922A4 (en) 2022-05-04

Similar Documents

Publication Publication Date Title
PH12020551911A1 (en) Use of riluzole oral disintigrating tablets for treating diseases
MX2024007642A (es) Uso de tabletas de desintegracion oral de riluzol para tratar enfermedades.
NZ777871A (en) Small molecule modulators of il-17
MX2020012180A (es) Compuestos biciclicos fusionados utiles como inhibidores de la peptidasa 30 especifica de ubiquitina.
FI3504187T3 (fi) Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten
PH12019500025A1 (en) Cancer treatment combinations
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
MX2020010300A (es) Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas.
PH12021553056A1 (en) Modified release formulations and uses thereof
AU2020278236A8 (en) Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor
ZA202000028B (en) Use of vibegron to treat overactive bladder
MX2024010655A (es) Uso de profarmacos de riluzol para tratar enfermedad de alzheimer.
WO2017182873A3 (en) Peptide-oligourea foldamer compounds and methods of their use
ZA202204907B (en) Orally disintegrating pharmaceutical compositions of apixaban
JP2016505050A5 (https=)
MX2018005298A (es) Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa.
MX2021014093A (es) Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson.
TN2016000179A1 (en) Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor.
JOP20230099A1 (ar) تركيبات صيدلية
MX2021007324A (es) Terapia oral con acido 6,8-bis-benciltio-octanoico.
EA202092944A1 (ru) Применение пероральных распадающихся таблеток рилузола для лечения заболеваний
AU2017260751A1 (en) Tablet-in-tablet pharmaceutical composition comprising cyclophosphamide and capecitabine
AR076016A1 (es) Domperidona a una dosis diaria baja para su uso en el tratamiento o la prevencion de una enfermedad asociada a una alteracion de la respuesta inmunitaria
GB2574944A (en) Methods and compositions for the treatment of pain and/or inflammation
EA201992754A1 (ru) Фармацевтические композиции